Prospector
Profile
07.1291
|
| |
| Trans-Science Corp. |
NAICS |
541710 |
| 4230 Sycamore Dr.
San Diego, CA 92105 |
Description |
Biotechnology |
| (619) 640-0155 |
Employees |
0 |
|
Revenue |
(mil) |
0.0000 |
| |
Income |
(mil) |
-0.0050 |
| |
Assets |
(mil) |
0.0260 |
| |
Liability |
(mil) |
0.0110 |
| |
(for the year ended 2006-12-31) |
| |
|
Category:
Audit Concerns
|
| |
|
Event:
Stan J.H. Lee CPA expressed doubts on the ability of Trans-Science Corp. to continue as a going concern after auditing its financial statements. The auditor explains that the Company does not have significant cash or other material assets, nor does it have operations or a source of revenue sufficient to cover its operating costs and allow it to continue as a going concern.
|
| |
|
Intellectual Property:
The Company acquired the assets of Secondary Immune Systems (SIS), whose only asset is U.S. Patent Number 6539252. The Patent is for a device which utilizes a low
intensity direct electric current to generate cations (positively charged ions) of silver and copper in the blood stream. It is believed that these particles are effective in destroying blood borne pathogens such as viruses and bacteria. [SEC Filing 10SB12G 02-02-07]
|
| |
|
Description:
The Company, through its subsidiary, is engaged in the research and development of an apparatus for destroying blood borne pathogens.
|
| |
|
Officers:
Phillip F. Burris (Pres. & Dir.); Rubelyn de la Cruz (Sec., Treas. & Dir.)
|
| |
|
Auditor:
Stan J.H. Lee, CPA
|
| |
|
Securities:
Common Stock-Symbol TRNC.OB; OTC BB;
2,300,000 common shares outstanding as of June 30, 2007.
|
| |
| |
| |
| return to main page |
